I-Mab Biopharma has dosed the first patient in mainland China in its ongoing, pivotal Phase 2 trial assessing MorphoSys‘s investigational antibody therapy…
I-Mab Biopharma is expanding to mainland China its ongoing clinical studies assessing MorphoSys‘ investigational antibody therapy MOR202 (TJ202) as treatment for people…
MorphoSys, the creator of HuCAL (Human Combinatorial Antibody Library), will give two oral and one poster presentation on the company’s proprietary antibody hemato-oncological programs, MOR208 and…
In a poster presentation at the 2016 ASCO Annual Meeting in Chicago, MorphoSys presented updated safety and efficacy data from an ongoing open-label, multicenter, Phase…
